BRISBANE, Calif., July 9, 2026 /PRNewswire/ -- Freenome, an early cancer detection company developing blood-based screening tests, today announced favorable results from its pivotal clinical ...
Freenome has partnered with Abbott to commercialize the test, which is expected to be available in the US this fall. The Food and Drug Administration (FDA) has approved Freenome’s SimpleScreen ™ CRC, ...
A novel, blood-based test developed using fragmentomic features of cell-free DNA (cfDNA) detects colorectal cancer (CRC) with a 90.4% sensitivity and shows consistent performance across stages and ...
cf-bDNA testing can reduce CRC incidence and mortality but is less effective and more costly than colonoscopy and FIT. The test may increase screening participation among those who avoid traditional ...
– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results